Theratechnologies Valeur / Action
Quel est le Valeur / Action de Theratechnologies?
Le Valeur / Action de Theratechnologies Inc. est 0.16
Quelle est la définition de Valeur / Action?
La valeur comptable par action est l'actif de la société moins le passif divisé par le nombre d'actions en circulation.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Valeur / Action des entreprises dans Health Care secteur sur NASDAQ par rapport à Theratechnologies
Que fait Theratechnologies?
theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.
Entreprises avec valeur / action similaire à Theratechnologies
- China City Infrastructure a Valeur / Action de 0.16
- Healthcare Merger a Valeur / Action de 0.16
- FinServ Acquisition Corp a Valeur / Action de 0.16
- Sezzle a Valeur / Action de 0.16
- ZincX Resources a Valeur / Action de 0.16
- Dingdong (Cayman) Ltd a Valeur / Action de 0.16
- Theratechnologies a Valeur / Action de 0.16
- Vivos Therapeutics a Valeur / Action de 0.16
- Tritent International a Valeur / Action de 0.16
- Garibaldi Resources a Valeur / Action de 0.16
- Fujian a Valeur / Action de 0.16
- Nova Minerals a Valeur / Action de 0.16
- Kwan Yong a Valeur / Action de 0.16